Impact of Symbiotic Administration on Intestinal Function of Head and Neck Patients Surgically Treated
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02654652 |
Recruitment Status :
Completed
First Posted : January 13, 2016
Results First Posted : June 5, 2019
Last Update Posted : June 5, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Cancer Synbiotics Nutrition Therapy | Dietary Supplement: Symbiotic Dietary Supplement: Maltodextrin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | Intestinal Function of Patients With Uper Air and Digestive Neoplasia Submitted to Surgical Treatment: Symbiotic Use Impact |
Study Start Date : | October 2014 |
Actual Primary Completion Date : | January 2016 |
Actual Study Completion Date : | July 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Symbiotic
Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
|
Dietary Supplement: Symbiotic
Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
Other Name: LactoFos |
Placebo Comparator: Maltodextrin
Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
|
Dietary Supplement: Maltodextrin
Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment |
- Serum DAO Enzyme Concentration [ Time Frame: 7 days ]The intestinal permeability using serum DAO enzyme concentration (ng/mL) was determined by sandwich enzyme-linked immunosorbent assay (ELISA) kit (SEA656Hu), according to Cloud-Clone Corporation® (Huston, TX) specifications.
- Infection Rate [ Time Frame: 7 days ]According to Dindo et al, 2004

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- head and neck cancer with primary surgical treatment, enteral nutrition by enteral tube.
Exclusion Criteria:
- three months antibiotic use earlier the surgery, recently radiotherapy or quimiotherapy, inflammatory bowel disease.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02654652
Brazil | |
UFMG Hospital | |
Belo horizonte, Minas Gerais, Brazil, 30640100 |
Principal Investigator: | Priscilla C Lages, bachelor | Federal University of Minas Gerais |
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Maria Isabel Toulson Davisson Correia, PhD, Federal University of Minas Gerais |
ClinicalTrials.gov Identifier: | NCT02654652 History of Changes |
Other Study ID Numbers: |
CAAE 24375713.0.0000.5149 |
First Posted: | January 13, 2016 Key Record Dates |
Results First Posted: | June 5, 2019 |
Last Update Posted: | June 5, 2019 |
Last Verified: | February 2019 |
Head and Neck Neoplasms Neoplasms by Site Neoplasms |